TScan Therapeutics cuts 75% of staff, pauses Phase 3 study, CFO and CMO out

What happened

TScan Therapeutics, Inc. (TCRX) announced on September 2, 2026, a strategic reorganization that includes cutting approximately 75% of its workforce, pausing further enrollment in its Phase 3 ALLOHA-2 study of TSC-101, and terminating the employment of its Chief Financial Officer Jason A. Amello and Chief Medical Officer Chrystal Louis, M.D., MPH. The company said it will prioritize preclinical development of its in vivo solid tumor program and advance two product candidates into IND-enabling studies.

The company also disclosed that it received a notice from Nasdaq on August 27, 2026, stating that its common stock failed to maintain the $1.00 minimum bid price required for continued listing. The stock has 180 days, until February 23, 2027, to regain compliance.

Shares of TScan fell 45.83% to $0.3608 on the announcement, on volume nearly ten times the average.

The strategic reorganization

TScan is a Waltham, Massachusetts-based biopharmaceutical company developing T-cell receptor (TCR) therapies for cancer. The company said it is shifting its focus to its in vivo solid tumor program, a technology that engineers patients' T-cells directly in the body, rather than manufacturing personalized cell therapies in a lab.

As part of the refocus, TScan is pausing its heme malignancies program, which includes the Phase 3 ALLOHA-2 study. The company said 7 patients were enrolled in the treatment arm and it will continue to treat and follow them at reduced costs while exploring partnerships.

The company expects to incur approximately $4.1 million in employee-related costs from the reorganization, primarily pay continuation and benefits. TScan said the restructuring should produce cumulative cost savings of $55.0 million through the end of 2027.

TScan believes its cash, cash equivalents and marketable securities as of June 30, 2026, will fund operations into the fourth quarter of 2027.

Why this happened

The company said the reorganization is due to capital constraints. It said data from the Phase 1 ALLOHA study of TSC-101 were encouraging but that it is pausing the heme malignancies program because of limited funds.

The filing does not link the Nasdaq delisting notice directly to the reorganization, but the stock had been trading near or below $1.00 per share. The company said it will monitor the bid price and consider options to regain compliance.

What this means

An 8-K is a form companies file with the SEC to announce major events that shareholders should know about. This 8-K covers multiple items: costs of the exit activities (Item 2.05), the Nasdaq delisting notice (Item 3.01), executive departures (Item 5.02), and other disclosures (Items 7.01 and 8.01).

The workforce reduction of approximately 75% is a major cut. When a company like TScan, which develops cell therapies, eliminates most of its staff and pauses a late-stage trial, it signals a significant contraction of its business. The departure of the CFO and CMO, with the CEO taking on the principal financial officer role, is consistent with a leaner operation.

The Nasdaq minimum bid price rule requires a listed stock to close at or above $1.00 for at least 10 consecutive trading days to regain compliance. If TScan does not meet that by February 23, 2027, it may qualify for a second 180-day period if it transfers to the Nasdaq Capital Market and meets other requirements. If it fails again, its stock could be delisted, which would make it harder to trade but would not necessarily end the company.

The filing says the data from the Phase 1 ALLOHA study showed that patients treated with TSC-101 had more durable remissions and decreased relapse rates compared to controls. However, the company is pausing further enrollment in the Phase 3 study because of capital constraints, not because the drug failed. The filing does not say why the study was being paused beyond the capital issue.